Herceptin acts as an anti-angiogenic cocktail
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Malignant tumours secrete factors that enable them to commandeer their own blood supply (angiogenesis), and blocking the action of these factors can inhibit tumour growth. But because tumours may become resistant to treatments that target individual angiogenic factors by switching over to other angiogenic molecules, a cocktail of multiple anti-angiogenic agents should be more effective. Here we show that herceptin, a monoclonal antibody against the cell-surface receptor HER2 (for human epidermal growth factor receptor-2; ref. 4), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors. As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certain molecularly targeted agents, such as the anti-HER2 antibody trastuzumab, and metronomic chemotherapy can also induce vascular normalization via upregulation of thrombospondin expression28,116,117.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [116]
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Self-citationLeakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1
Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., & McDonald, D. M. (1999) · Science · doi:10.1126/science.286.5449.2511 · Cited by 1,359
Tumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Self-citationThrombospondins as matricellular modulators of cell function
Bornstein, P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12749 · Cited by 470
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 276
‘Accidental’ anti-angiogenic drugs
Kerbel, R. S., Viloria-Petit, A., Klement, G., & Rak, J. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00092-7 · Cited by 182
Angiogenic Heterogeneity: Regulation of Neoplastic Angiogenesis by the Organ Microenvironment
Fidler, I. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1040 · Cited by 109
Jain, R. K., & Carmeliet, P. (2001) · Scientific American · doi:10.1038/scientificamerican1201-38 · Cited by 94
Self-citation
Research works printed but not linked: 1
- Jain, R. K., Munn, L. L. & Fukumura, D. Nature Rev. Cancer (in the press).
Cited by
Items 601–622 of 622
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26706375
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26706387
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26706390
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26706372
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26706381
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26706402
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26706399
Kim, D.-M., Lee, S.-Y., 임재청, Cho, E.-H., & Park, U.-J. (2023) · Figshare · doi:10.6084/m9.figshare.26603731
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25608822
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26706378
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26706384
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25608702
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26706393
Kornfeld, S. (2011) · theses.fr (ABES) · doi:10.70675/563f9c32z43f3z423bza4bdz1718b7571f19 · Cited by 2
Mathematical modeling of antibody nanoconjugates transport in tumors
Vaghi, C. (2020) · theses.fr (ABES) · doi:10.70675/b385c631za830z412dzb918zb2d2f5181f67
Kanyavuz, A. (2022) · theses.fr (ABES) · doi:10.70675/45f8ab45zab05z478dzb41azaf4496ced5ac
TRASTUZUMAB - REVIEW OF USE AND EFFECTIVENESS IN THE TREATMENT OF HER2-POSITIVE NEOPLASM
Król, W., Kulka, K., Jurczak, D., Koronczok-Matusiak, J., Kafara, Z., Kowalczyk, D., Lechowska, Z., Kafara, A., Szarek, R., & Michta, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5170
Kamohara, R., Okazaki, M., Ueda-Sawa, A., Sato, R., Matsuo, T., Hashimoto, S., Iguchi‐Manaka, A., & Bando, H. (2026) · International Cancer Conference Journal · doi:10.1007/s13691-026-00885-z
Role of p53 in Adaptation to the Tumor Microenvironment
Mendoza, E. E. (2010) · UA Campus Repository (The University of Arizona)
Iivanainen, E. (2008) · UTUPub (University of Turku)
Metadata
- Authors
- Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature
- Published
- 2002-03
- Volume
- 416
- Issue
- 6878
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034801324
- Cited by
- 623
- References
- 11
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 26 · 2023: 10 · 2022: 14 · 2021: 12 · 2020: 18 · 2019: 12 · 2018: 20 · 2017: 23 · 2016: 18 · 2015: 24 · 2014: 27 · 2013: 30 · 2012: 35
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (P01CA080124)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- trastuzumab, anti-angiogenic therapy, HER2, human epidermal growth factor receptor 2, tumor angiogenesis, tumor regression, combination therapy, breast cancer, monoclonal antibodies, tumor resistance
- MeSH terms
- Trastuzumab, Animals, Antibodies, Monoclonal, Humans, Lymphokines, Mammary Neoplasms, Experimental, Neovascularization, Pathologic, Signal Transduction, Gene Expression, Endothelial Growth Factors, Mice, SCID, Genes, erbB-2, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.